<DOC>
	<DOCNO>NCT01516931</DOCNO>
	<brief_summary>The purpose study evaluate efficacy repetitive transcranial magnetic stimulation prevention relapse symptom depression . Primary Outcome Measures : Time subject randomization treatment first occurrence relapse Relapse Prevention Period . Secondary Outcome Measures : Symptom change measure Hamilton Depression Rating Scale ( HDRS ) ; Illness severity change measure Clinical Global Impression Severity depression ( CGI-S-DEP ) ; Change subject function use Personal Social Performance Scale .</brief_summary>
	<brief_title>Efficacy Repetitive Transcranial Magnetic Stimulation Prevention Relapse Depression</brief_title>
	<detailed_description>Transcranial magnetic stimulation noninvasive technique influence specific area brain side effects.Several factor characterize repetitive transcranial magnetic stimulation ( rTMS ) strategic aid treatment depression.Depression chronic illness generally require life-long treatment . However , current day study evaluate effect rTMS maintenance treatment depression . This randomized , double-blind , placebo-controlled , parallel-group , multicenter study evaluate efficacy rTMS , monotherapy , relative placebo delay time relapse patient depression . Patients acute symptom depression enrol . The study consist 4 period : 7 day screening/tolerability period , 6-week open-label flexible dose lead-in period , 6-week open-label fix dose stabilization period , 12 month double-blind relapse prevention period . The study consist 4 phase : screening/tolerability phase 7 day ; open-label , flexible-dose lead-in phase 8 week ; open-label , fixed-dose stabilization phase 6 week ; single-blind relapse prevention phase 12 month . During open-label phase , patient treat venlafaxine . Remitterswith Hamilton Rating Scale Depression [ HAM-D17 ] score â‰¤ 7will eligible enter single-blind phase randomly assign one three group : group 1 active rTMS venlafaxine ; group 2 sham rTMS venlafaxine ; group 3 venlafaxine alone . Efficacy evaluate study use relapse assessment ( time subject randomization treatment first occurrence relapse ) . Secondary outcome measure include : symptom change , measure Hamilton Rating Scale Depression [ HAM-D17 ] ; illness severity change , measure Clinical Global Impression Severity Depression ( CGI-S-DEP ) ; change subject functioning , assess Personal Social Performance Scale . Safety assess throughout study monitor adverse event , clinical laboratory test , electrocardiography , measurement vital sign ( temperature , pulse blood pressure ) weight . Suicidality assess Columbia Suicide Severity Rating Scale ( C-SSRS ) . A 10 milliliter pharmacogenomic blood sample ( sample DNA research ) collect patient give separate write informed consent part study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>DSMIV diagnosis depression Experiencing acute exacerbation depression symptom Baseline score least 14 point Hamilton Depression rating Scale17 item Healthy base physical examination , electrocardiogram ( ECG ) , laboratory test , medical history , vital sign measurement Comprised ferromagnetic metallic implant Pacemakers Previous neurosurgery History seizure Major head trauma Alcoholism Drug addiction Any psychiatric neurological disorder depression anxiety Psychotic depression Suicidal propensity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>repetitive Transcranial Magnetic Stimulation ( rTMS )</keyword>
	<keyword>Depression</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Relapse</keyword>
</DOC>